Display options
Cite
Miyagawa A, Adachi T, Kobayashi Y, et al. Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis. J Dermatol. 2021;doi: 10.1111/1346-8138.16248.
Miyagawa, A., Adachi, T., Kobayashi, Y., Takamiyagi, S., Arakawa, H., Futatsugi, K., & Inazumi, T. (2021). Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis. The Journal of dermatology, . https://doi.org/10.1111/1346-8138.16248
Miyagawa, Akihiro, et al. "Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis." The Journal of dermatology vol. (2021). doi: https://doi.org/10.1111/1346-8138.16248
Miyagawa A, Adachi T, Kobayashi Y, Takamiyagi S, Arakawa H, Futatsugi K, Inazumi T. Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis. J Dermatol. 2021 Nov 26; doi: 10.1111/1346-8138.16248. Epub 2021 Nov 26. PMID: 34837271.
Copy Download .nbib Format: NLM
Share it on

J Dermatol. 2021 Nov 26; doi: 10.1111/1346-8138.16248. Epub 2021 Nov 26.

Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis.

The Journal of dermatology

Akihiro Miyagawa, Takeya Adachi, Yuki Kobayashi, Saeko Takamiyagi, Hiroki Arakawa, Koji Futatsugi, Toyoko Inazumi

Affiliations

  1. Department of Dermatology, Tachikawa Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan.
  2. Department of Medical Regulatory Science, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  3. Keio Frontier Research & Education Collaborative Square at Tonomachi, Keio University, Kanagawa, Japan.
  4. Department of Nephrology, Tachikawa Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan.

PMID: 34837271 DOI: 10.1111/1346-8138.16248

[No abstract available.]

References

  1. Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, et al. Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020;20:139. - PubMed
  2. Endo Y, Oka A, Uehara A, Toki S, Motegi S-I, Ishikawa O, et al. Fatal case of toxic epidermal necrolysis due to apalutamide used as a novel prostate cancer drug. J Dermatol. 2020;47:e359-60. - PubMed
  3. Sagawa N, Watanabe Y, Mizuno Y, Takahashi S, Watanabe T, Ikeda N, et al. A case of toxic epidermal necrolysis associated with apalutamide administration. J Cutan Immunol Allergy. 2020;3:134-5. https://doi.org/10.1002/cia2.12138 - PubMed
  4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6. - PubMed
  5. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-53. - PubMed

Publication Types

Grant support